Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic

Abstract

Halda Therapeutics has started a clinical trial of its first-in-modality RIPTAC drug HLD-0915 in prostate cancer, to see if bifunctional drugs can provide tissue-specific activity.